Neurturin Polypeptide Mutations for Brain Biodistribution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neurturin therapies face limitations due to high affinity for heparan sulfate, which restricts diffusion and efficacy in treating neurological disorders, as seen in clinical trials where neurturin fails to distribute evenly in the brain, suggesting a need for neurturin variants with reduced heparin and heparan sulfate binding affinity while maintaining neurotrophic activity.
Innovation Solution
Development of neurturin polypeptides with specific mutations in the amino acids 51 to 63 region, such as R52A, R56A, and R58A, that reduce heparin binding affinity while retaining the ability to induce RET phosphorylation and neurotrophic activity, allowing broader biodistribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurturin is used to treat neurological disorders, then neurotrophic activity is improved, but heparan sulfate binding affinity restricts diffusion and biodistribution
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acids (positions 51-63) in the neurturin sequence to alter the heparin/heparan sulfate binding affinity parameter. This allows the molecule to maintain neurotrophic activity while reducing non-specific binding to extracellular matrix components, thereby improving diffusion and biodistribution throughout the brain tissue.
Solution Approach 2:
The invention applies local quality by making targeted modifications to a specific region (amino acids 51-63) of the neurturin molecule rather than altering the entire structure. This localized change in the heel region selectively reduces heparin binding affinity while preserving the overall neurotrophic function mediated by other regions of the molecule.
2Stability of the object's composition
If neurturin binds to heparin with high affinity, then stability is improved, but diffusion capability deteriorates
Solution Approach 1:
The patent changes the binding affinity parameter of neurturin for heparin/heparan sulfate by introducing point mutations in the heel region. This reduces the strength of non-specific interactions with extracellular matrix components, enabling faster diffusion through brain tissue while maintaining sufficient stability for therapeutic activity.
Solution Approach 2:
The invention effectively extracts or removes the excessive heparin binding capability from the neurturin molecule by mutating the heel region amino acids. This separation allows the molecule to retain essential neurotrophic functions while eliminating the detrimental high-affinity binding to heparan sulfate that restricts diffusion.
3Reliability
If neurturin is administered for clinical treatment, then therapeutic efficacy is improved, but uneven distribution in brain tissue occurs
Solution Approach 1:
The patent modifies the physicochemical parameters of neurturin by mutating amino acids in the heel region, specifically reducing heparin binding affinity. This parameter change enables more uniform distribution of the therapeutic agent throughout the brain tissue, ensuring consistent efficacy across different regions rather than localized hotspots.
Solution Approach 2:
The invention applies local quality modifications to the neurturin molecule at the amino acid level (positions 51-63) to achieve global improvement in tissue distribution uniformity. The localized mutation in the heel region creates a neurturin variant with enhanced ability to distribute evenly throughout the brain while maintaining therapeutic activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated neurturin polypeptides exhibit decreased heparin binding, enhancing their ability to diffuse and maintain neurotrophic activity, potentially improving therapeutic outcomes for neurological disorders by ensuring broader tissue distribution and effectiveness.
Implementation Method 1
the high affinity of neurturin for heparan sulfate prevents adequate diffusion of the molecule to a broad enough region to be efficacious
Data Source
AI summary
Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.